Head-To-Head Contrast: Harvard Bioscience (HBIO) and Its Peers
Harvard Bioscience (NASDAQ: HBIO) is one of 80 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Harvard Bioscience to similar companies based on the strength of its valuation, profitability, institutional ownership, dividends, analyst recommendations, earnings and risk.
Insider and Institutional Ownership
61.0% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 9.8% of Harvard Bioscience shares are owned by insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Harvard Bioscience has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Harvard Bioscience’s peers have a beta of 1.29, suggesting that their average stock price is 29% more volatile than the S&P 500.
This table compares Harvard Bioscience and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Harvard Bioscience Competitors||-312.53%||-28.44%||-10.33%|
This is a breakdown of recent ratings and price targets for Harvard Bioscience and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Harvard Bioscience Competitors||271||1878||3374||108||2.59|
Harvard Bioscience presently has a consensus target price of $5.75, suggesting a potential upside of 76.92%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 8.13%. Given Harvard Bioscience’s stronger consensus rating and higher probable upside, research analysts clearly believe Harvard Bioscience is more favorable than its peers.
Valuation & Earnings
This table compares Harvard Bioscience and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Harvard Bioscience||$104.52 million||-$4.30 million||-36.11|
|Harvard Bioscience Competitors||$2.13 billion||$229.91 million||-33.97|
Harvard Bioscience’s peers have higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Harvard Bioscience beats its peers on 8 of the 13 factors compared.
About Harvard Bioscience
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.